Delivery Order SPE2DB20D3101-SPE2DB25FRTU2
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Envarsus XR 1 mg tablets in a quantity of 100 units. This competitively awarded, non-set-aside contract carries a ceiling value of $1,718.48 with firm fixed pricing and is scheduled for completion by September 11, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Envarsus XR 1 mg tablets (100-count) with a ceiling value of $1,288.86. This non-set-aside, competitively awarded contract is structured as a firm fixed price delivery order with an ultimate completion date of September 22, 2025. The pharmaceutical product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Envarsus XR 4 mg tablets (100-count units) with a contract ceiling value of $5,135.85. This is a firm fixed-price delivery order with an ultimate completion date of September 10, 2025, and represents no set-aside contract, indicating it was competitively awarded. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Envarsus XR 4 mg tablets (100-count) with a ceiling value of $1,711.95 and a firm fixed price structure. The contract represents a non-set-aside, competitively awarded delivery order with an ultimate completion date of September 24, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under...
- The Defense Logistics Agency awarded a delivery order valued at $3,423.90 to AmerisourceBergen Drug Corp for the supply of Envarsus XR 4 mg tablets (100-count bottles) on August 25, 2025, with completion scheduled for September 16, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award to the pharmaceutical distributor's corporate office in Conshohocken, Pennsylvania. The contract is issued as a child order under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Envarsus XR 1 mg tablets (30-count packaging) under a firm fixed-price contract with a ceiling value of $1,165.05. The delivery order, classified as a non-set-aside competitive award, is scheduled for completion by September 9, 2025, with performance and delivery to occur at AmerisourceBergen's distribution facility in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $1,288.86 to AmerisourceBergen Drug Corp for the supply of Envarsus XR 1 mg tablets (100-count packaging). This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive $999.99 billion pharmaceutical supply vehicle supporting military healthcare programs globally through December 2026....
- The U.S. Department of Defense's Medical Supply Chain awarded a delivery order valued at $5,135.85 to AmerisourceBergen Drug Corp for the supply of Envarsus XR 4 mg tablets (100-count units) on August 22, 2025, with an ultimate completion date of September 15, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Envarsus XR 4 mg tablets (100 count) with a contract value of $4,283.14 and an ultimate completion date of September 9, 2025. This is a firm fixed price delivery order issued under a non-set-aside competitive procurement. The award represents a child contract under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,361.58 for Envarsus XR 1 mg tablets (30-count supply) on July 29, 2025, with an ultimate completion date of August 19, 2025. This firm fixed-price delivery order represents a competitively awarded contract with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Envarsus XR is an extended-release immunosuppressant medication used primarily in...
- SPE2DB20D3101Indefinite Delivery Contract
- SPE2DB20D3101-SPE2DB25FRTU2Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Envarsus XR 1 mg tablets in quantities of 100 units. This competitively awarded, firm fixed-price delivery order carries a ceiling value of $1,718.48 and is scheduled for completion by September 19, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child contract action under a larger vehicle, this delivery order leverages AmerisourceBergen's existing indefinite delivery contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical support agreement running through December 2026 that enables the company to supply a comprehensive range of pharmaceutical products and medical supplies to military healthcare programs worldwide. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, serves as a key supplier to the Defense Health Agency and other government healthcare systems. The company's federal contract portfolio demonstrates extensive experience delivering both brand-name and generic medications across multiple therapeutic domains, including specialty pharmaceuticals and medical supplies. This delivery order for Envarsus XR, an immunosuppressant medication used in transplant patients, represents a routine fulfillment under the company's established prime vendor relationship with the Defense Logistics Agency's medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.7k | 8/28/25 |